Inovio Pharmaceuticals (INO) Current Deferred Revenue (2010 - 2022)

Inovio Pharmaceuticals has disclosed Current Deferred Revenue across 13 years of filings, most recently posting $9.0 million for Q2 2022.

• In Q2 2022, Current Deferred Revenue rose 8131.27% year-over-year to $9.0 million; the TTM figure through Jun 2022 stood at $9.0 million (up 8131.27% YoY), while the FY2021 annual figure was $21628.0, down 53.62% from the prior year.
• Current Deferred Revenue came in at $9.0 million for Q2 2022 at Inovio Pharmaceuticals, up from $15378.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $24.1 million in Q1 2018 to a low of $14853.0 in Q2 2020.
• Average Current Deferred Revenue over 5 years is $2.1 million, with a median of $99232.0 recorded in 2019.
• Year-over-year, Current Deferred Revenue tumbled 99.54% in 2019 and jumped 8131.27% in 2022.
• Over 5 years, Current Deferred Revenue stood at $1.1 million in 2018, then slumped by 91.33% to $92353.0 in 2019, then sank by 49.51% to $46628.0 in 2020, then sank by 53.62% to $21628.0 in 2021, then surged by 41432.36% to $9.0 million in 2022.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $9.0 million in Q2 2022, $15378.0 in Q1 2022, and $21628.0 in Q4 2021.